Oncobiologics (OTLK)
(Real Time Quote from BATS)
$8.09 USD
+0.08 (1.00%)
Updated Sep 10, 2024 10:54 AM ET
3-Hold of 5 3
D Value B Growth A Momentum C VGM
Brokerage Reports
Oncobiologics, Inc. [OTLK]
Reports for Purchase
Showing records 21 - 40 ( 40 total )
Company: Oncobiologics, Inc.
Industry: Medical - Biomedical and Genetics
Fiscal 4Q Update: Outlook in a Strong Position to File Lytenava BLA in Calendar 1Q22; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Oncobiologics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Oncobiologics, Inc.
Industry: Medical - Biomedical and Genetics
Outlook Looks to Wet AMD BLA Filing in 1Q22; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Oncobiologics, Inc.
Industry: Medical - Biomedical and Genetics
Strong NORSE TWO Topline Should Pave the Way for Approval; Reit Buy, PT to $6
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Oncobiologics, Inc.
Industry: Medical - Biomedical and Genetics
Outlook Appoints New CEO While Lawrence Kenyon to Continue as CFO and Board Member
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Oncobiologics, Inc.
Industry: Medical - Biomedical and Genetics
Outlook Lays Out Lytenava Value Proposition and Strategy at Virtual Clinical Day; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Oncobiologics, Inc.
Industry: Medical - Biomedical and Genetics
Looking to a Lytenava Filing in 1Q22; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Oncobiologics, Inc.
Industry: Medical - Biomedical and Genetics
NORSE THREE Validates Lytenava Safety Profile; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Oncobiologics, Inc.
Industry: Medical - Biomedical and Genetics
Outlook Aims to File Lytenava BLA by Year?s-end With Balance Sheet Bolstered by February?s Raise
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Oncobiologics, Inc.
Industry: Medical - Biomedical and Genetics
Three Key Takeaways From Virtual KOL Roundtable on Lytenava; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Oncobiologics, Inc.
Industry: Medical - Biomedical and Genetics
NORSE 1 Offers Initial Validation for Lytenava, But Depth of Data Is Somewhat Lacking; Reiterate Buy, Lower PT to $5
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Oncobiologics, Inc.
Industry: Medical - Biomedical and Genetics
Outlook Completes Enrollment in Pivotal NORSE 2 Trail; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Oncobiologics, Inc.
Industry: Medical - Biomedical and Genetics
Private Placement Extends Cash Runway Through RTTNORSE-1 Readout; Reiterate Buy, Target to $7
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Oncobiologics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Oncobiologics, Inc.
Industry: Medical - Biomedical and Genetics
A Measure of Relief as NORSE-1 Remains on Schedule for 3Q Data and NORSE-2 Is Only Modestly Delayed; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Oncobiologics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Oncobiologics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Oncobiologics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Oncobiologics, Inc.
Industry: Medical - Biomedical and Genetics
3Q Update Brings Further Progress for Pivotal Trials
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Oncobiologics, Inc.
Industry: Medical - Biomedical and Genetics
An Innovative Strategy for a Biosimilar; Initiate With a Buy and $8 Price Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D